Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donor-derived Virus-specific T-cells for Refractory Viral Infections Post-HSCT
NCT02007356Phase 2Recruiting
- Sponsor
- University Hospital Basel
- Start
- Dec 2014
- Primary completion
- Dec 2026
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of IFN-gamma positive selected T-cells (University Hospital, Basel) in adenovirus infection, Epstein-Barr virus infection, cytomegalovirus infection (CMV), sponsored by University Hospital Basel. Started Dec 2014; status: recruiting.
02
Drugs
IFN-gamma positive selected T-cells (University Hospital, Basel)
03
Conditions
adenovirus infectionEpstein-Barr virus infectioncytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT02007356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02007356.